Safety and Feasibility of the NeurolyserXR for Sacroiliac Joint Pain

Last updated: September 6, 2023
Sponsor: FUSMobile Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Ankylosing Spondylitis

Treatment

NeurolyserXR

Clinical Study ID

NCT05396495
SIJ-001
  • Ages 18-80
  • All Genders

Study Summary

Pilot study to evaluate the safety and the effectiveness of the Neurolyser XR as a treatment for sacroiliitis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult male and females, legally able and willing to participate in the study and comefor follow-up visits
  2. Able and willing to fill the research questionnaires and to communicate withinvestigator and research team
  3. Patient with bilateral or unilateral sacroiliac joint pain of > 6 months duration
  4. Patients presenting with a) a positive (>70% pain relief) to a previous nerve ablationprocedure of the sacroiliac joint and / or b) with a positive (>70% pain relief) to aprevious nerve block procedure of the sacroiliac joint within the last six months)
  5. Average pain score of 4 or higher in the last month, (on 0-10 scale).

Exclusion

Exclusion Criteria:

  1. Pregnant or breastfeeding patient
  2. Patients younger than 18 or older than 80 years
  3. Patients presenting with neurological deficits (including lumbosacral radiculopathybut not solitary radicular pain).
  4. Patients with history of lumbar and / or sacral spine surgery
  5. Patients with the presence of metal hardware at the lumbosacral spine
  6. Patients with history of pelvic pathology that may increase procedural risk and / orinfluence symptoms and / or generate unrelated adverse event (per the discretion ofthe study PI)
  7. Patients unable to understand and complete the research questionnaires in Hebrew.
  8. Patients presenting with any severe medical condition preventing the patient fromsafely and effectively being treated in the study or reporting study outcome.
  9. Patient with extensive scarring in the skin and tissue overlying the treatment area.
  10. Patients enrolled in or planned to be enrolled in another clinical trial during theduration of this research project

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: NeurolyserXR
Phase:
Study Start date:
October 24, 2022
Estimated Completion Date:
December 01, 2024

Study Description

Pilot, Interventional, Prospective, Open label, Single Arm study to evaluate Non-invasive thermal ablation of the posterior sacral nerve branches as a treatment of painful sacroiliac joint (SIJ) using High Intensity Focused Ultrasound delivered by the Neurolyser XR.

Patient would be treated and then followed for up to 6 months. Primary safety endpoint will be measured by the incidence and severity of treatment related adverse events Primary effectiveness endpoint will be measured by the changes in average pain score and Rolland Morris Disability Questionnaire between baseline and 6 and 12 months

Connect with a study center

  • Sheba Medical Center

    Givatayim,
    Israel

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.